With EU nod, Biogen is ready to roll Tecfidera onto the continent

Biogen Idec's ($BIIB) fast-selling new multiple sclerosis drug won approval in a broad new market: Europe. After sewing up its Tecfidera intellectual property rights there last year, Biogen can now roll out the drug for first-line MS treatment across the continent. But as CEO George Scangos has pointed out, the EU launch won't yield sales results as immediately as the U.S. launch did, because Tecfidera has to win reimbursement in individual countries, a process that takes time. Release